Report Id: SNS/HC/2652 | July 2022 | Region: Global | 126 Pages
Report Scope & Overview:
The Chlamydia Infection Treatment Market Size was valued at USD 57.76 billion in 2022 and is expected to reach USD 128.40 billion by 2030, and grow at a CAGR of 10.5% over the forecast period 2023-2030.
The market for chlamydia infection therapy is expanding as the prevalence of sexually transmitted illnesses rises. Furthermore, rising government actions to raise STD awareness and public knowledge about STDs are moving the market ahead. In response to the rising economic impact of STDs, the government has boosted its efforts to raise awareness of the disease. The growth of the chlamydia infection treatment market is being driven by a rise in government-sponsored awareness initiatives and measures such as free diagnostic camps to promote regular health check-ups. The demand for regular health check-ups has increased, as has public knowledge of sickness screening.
Increased prevalence of sexually transmitted diseases including chlamydia
Rising government initiatives to raise STD awareness
Low disease screening rates in developing countries
The social stigma linked with STDs
Creating innovative and alternative treatments for Chalymdia
Antibiotic therapy is currently used in the treatment of chlamydia.
IMPACT OF COVID-19:
The increased prevalence of COVID-19 is expected to have an impact on market growth over the forecast period. As the coronavirus outbreak persists, the majority of pharmaceutical businesses have suffered considerable losses, putting the chlamydia infection treatment market in jeopardy. During the early stages of the pandemic, several businesses curtailed or ceased manufacturing and supply operations. However, the current COVID-19 scenario is expected to normalise as medical professionals and health authorities in the countries take the appropriate actions to combat the virus. During the COVID-19 pandemic, social distancing guidelines and resource reallocation have caused significant disruption to sexual health clinics around the world.
Furthermore, a lack of Active Pharmaceutical Ingredients (APIs) and completed goods, particularly antibiotics, has harmed the chlamydia infection treatment business. To avoid product shortages, the FDA and European Commission suggested and issued regulations concentrating on demand optimization and rational supply. Several restrictions were revised as part of these regulatory adjustments in order to improve imports and maintain supply chain integration.
Chlamydia trachomatis is the most common sexually transmitted bacterium and is a gram-negative bacteria that causes chlamydia. These are typical causes of genital tract infections and can look like a gonorrhoea infection. They are also linked to blindness and are the cause of inclusion conjunctivitis. Because of the disease's high incidence, the chlamydia infection treatment market is predicted to have a significant market share in 2021.
Chlamydia pneumoniae is a gram-negative bacteria that commonly causes pneumonia as well as community-acquired pneumonia.
The growing epidemics of community-acquired pneumonia are expected to drive the Chlamydia pneumoniae segment.
The oral method of administration is one of the most popular and widely utilised drug delivery routes. The gastrointestinal tract absorbs a medication administered via this route into the systemic circulation. The oral method of administration is the most recommended since it is simple and convenient for the patient, non-invasive, can be self-administered, and is generally safe and inexpensive. In 2021, the oral route of administration segment held the greatest proportion of the chlamydia infection treatment market.
Injectable administration is one of the most prevalent health-care treatments worldwide. The three most common injection routes in pharmaceutical delivery are intravenous (IV), subcutaneous (SC), and intramuscular (IM). These have various advantages, including quick action and the ability to be administered to unconscious patients. In 2021, the injectable route of administration segment accounted for a sizable share of the chlamydia infection treatment market.
A hospital pharmacy is a dispensary that supplies and administers pharmaceuticals to both inpatients and outpatients. Hospital pharmacies provide patients with quick access to medications and meet the needs of a large patient population. The expanding number of hospitals and the increase in hospital admissions boost the growth of the chlamydia infection treatment market sector.
Online pharmacies are internet-based merchants who deliver and distribute medications to customers through online platforms. Because of the internet's rapid spread, expanding digital health, and the convenience of mail-order trade, there is a significant demand for online pharmacies.
Retail pharmacies are physical stores that distribute and dispense medications to customers. Retail pharmacies are the most accessible to the general population and assist in the dispensing of prescription and over-the-counter drugs.
Merck & Co. Inc., Sanofi, Eli Lilly and Company, Novartis, GlaxoSmithKline Plc, AstraZeneca, TevaPharmaceuticals, Sun Pharma, Pfizer Inc, Gilead Sciences Inc.
by Causative Organisms
by Route of Administration
by Distribution Channel
North America is poised to take the lead in the chlamydia infection treatment market, owing to a well-developed healthcare sector and an increase in medical tests. The large number of biopharmaceutical and pharmaceutical businesses, as well as the alarming rise in STDs and the surge in government measures to educate the public about these illnesses, would all help to enhance the market position. The development of novel POC testing concepts, the increasing number of public health laboratories offering robust STD testing services, and the availability of insurance coverage are all key growth drivers. Various pipeline medications are currently undergoing comprehensive research to determine their potential to act as a replacement for antibiotics used to treat chlamydia.
As a result, advancements in pharmaceutical formulations and nanotechnology will provide attractive potential for the development of alternative treatments, ultimately leading to significant market expansion.
Asia Pacific is expected to develop at the quickest rate during the assessment period, owing to substantial improvements in healthcare infrastructure and an increase in the number of chlamydia patients. The extensive usage of STD screening, as well as the booming biopharma and pharma sectors, contribute to the value of the regional market. A significant increase in per capita healthcare expenditure will further support regional company growth.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2022||US$ 57.76 Billion|
|Market Size by 2030||US$ 128.40 Billion|
|CAGR||CAGR of 10.5% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• by Causative Organisms (Chlamydia trachomatis, Chlamydophila pneumoniae)
• by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others)
• by Route of Administration (Oral, Injectable, Others)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Merck & Co. Inc., Sanofi, Eli Lilly and Company, Novartis, GlaxoSmithKline Plc, AstraZeneca, TevaPharmaceuticals, Sun Pharma, Pfizer Inc, Gilead Sciences Inc.|
|Key Drivers||• Increased prevalence of sexually transmitted diseases including chlamydia.
• Rising government initiatives to raise STD awareness.
|RESTRAINTS||• Low disease screening rates in developing countries
• The social stigma linked with STDs
Frequently Asked Questions (FAQ) :
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
184.108.40.206 United Kingdom
220.127.116.11 South Korea
18.104.22.168 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8.Global Chlamydia Infection Treatment Market, by Causative Organisms
8.1 Chlamydia trachomatis
8.2 Chlamydophila pneumoniae
9.Global Chlamydia Infection Treatment Market, by Distribution Channel
9.1 Hospital Pharmacy
9.2 Online Pharmacy
9.3 Retail Pharmacy
10.Global Chlamydia Infection Treatment Market, by Route of Administration
11. Regional Analysis
11.2 North America
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4.2 South Korea
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.3 South Africa
11.6 Latin America
11.6.3 Rest of Latin America
12.1 Merck & Co. Inc.
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.3 Eli Lilly and Company
12.5 GlaxoSmithKline Plc
12.8 Sun Pharma
12.9 Pfizer Inc
12.10 Gilead Sciences Inc.
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of the good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.